Ultra‐high‐speed liquid chromatography combined with mass spectrometry detection analytical methods for the determination of nitrosamine drug substance‐related impurities

Author:

Marlés‐Torres Anna1,López‐García Rubén1,Bessa‐Jambrina Sergio1,Galán‐Rodríguez Cristóbal1ORCID

Affiliation:

1. Research and Development Department Moehs Ibérica Rubí Spain

Abstract

In the present study, five simple, feasible, and sensitive Ultra‐high‐speed liquid chromatography combined with mass spectrometry detection methods, using electrospray ionization are proposed. These methods were developed and validated for the determination of four different nitrosamine drug substance‐related impurities—N‐nitrosoacebutolol, N‐nitrosobisoprolol, N‐nitrosometoprolol, and N‐nitrososotalol—in five beta blockers active pharmaceutical ingredients—acebutolol HCl, bisoprolol fumarate, metoprolol tartrate, metoprolol succinate, and sotalol HCl. The proposed methods were validated as per regulatory guidelines. Acquity HSS T3 (3.0 × 100 mm, 1.8 μm) column and formic acid 0.1% in water combined with methanol or acetonitrile were used for chromatographic separation in all methods. The limit of detection and the limit of quantification were found to be in the range of 0.02–1.2 and 2–20 parts per billion, respectively. The accuracy and precision of the five methods have been demonstrated in the working range of each one, giving values of recovery within the range of 64.1%–113.3%, and the regression coefficients (R) were found to be in the range of 0.9978–0.9999. These methods could be used for controlling nitrosamine drug substance‐related impurities content for beta blockers drug substances batches manufactured at Moehs group.

Publisher

Wiley

Subject

Filtration and Separation,Analytical Chemistry

Reference19 articles.

1. Committee for Medicinal Products for Human Use assessment report. EMA/217823/2019.

2. Committee for Medicinal Products for Human Use interim opinion of the committee for medicinal products for human use pursuant to Article 5(3) of Regulation (EC) no 726/2004 for. EMA/CHMP/228681/2021.

3. European Medicines Agency.European Medicines Regulatory Network approach for the implementation of the CHMP Opinion pursuant to Article 5(3) of Regulation (EC) No 726/2004 for nitrosamine impurities in human medicines.EMA/425645/2020

4. Committee for Medicinal Products for Human Use assessment report.EMA/369136/2020

5. European Medicines Agency.Lessons learned from presence of N‐nitrosamine impurities in sartan medicines.EMA/526934/2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3